Return to homepagePandemic Pact

Detection of antibodies against SARS-CoV-2: IgG by ELISA and neutralizers in a type 2 Biosafety platform

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    MINCTCI - Chile

  • Principal Investigator

    N/A

  • Research Location

    Chile

  • Lead Research Institution

    Universidad del Desarrollo

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Development of the own ELISA test (viral antibody detection technique against coronavirus) at the ICIM and in conjunction with the Clínica Alemana de Santiago. This implies the medium-scale production of viral protein, which will allow the technique to be adjusted, and then move to a larger-scale stage carried out in Merken. This will allow a greater number of tests to be carried out and distributed to other laboratories for their use.